Tandem Diabetes Care Launches Compatibility of t:slim X2 Insulin Pump with Abbott FreeStyle Libre 3 Plus Sensor in Five Nations

Deep News07-01

Tandem Diabetes Care (Nasdaq: TNDM) has announced that its t:slim X2 insulin pump is now compatible with the Abbott Laboratories (NYSE: ABT) FreeStyle Libre 3 Plus continuous glucose monitoring sensor, with a formal launch in five international markets.

This release provides t:slim X2 users in the United Kingdom, Switzerland, Sweden, Finland, and Italy with additional CGM options.

The FreeStyle Libre 3 Plus sensor can be worn for up to 15 days, transmitting glucose readings to the insulin pump every minute, with data also viewable on the Tandem t:slim mobile app, offering users multiple convenient ways to monitor their current glucose trends.

The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest version of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin delivery every five minutes based on predicted glucose values.

This system is the only insulin pump featuring the AutoBolus function, which automatically calculates and delivers correction boluses to help manage glucose fluctuations from missed meal-time doses.

Dr. Jordan Pinsker, Chief Medical Officer at Tandem Diabetes Care, stated that users of automated insulin delivery desire flexibility in their devices. The addition of Abbott's latest-generation sensor expands CGM choices for users of Control-IQ+ technology.

Igor Friedmann, Senior Vice President of International Business at Tandem Diabetes Care, noted that this is an exciting next step in the company's global strategy to connect its insulin pump portfolio with the Abbott Laboratories FreeStyle Libre 3 Plus sensor, with plans to expand this accessibility to t:slim X2 users in more countries in the coming months.

Tandem Diabetes Care plans to extend compatibility to more countries by 2026, including Belgium, the Netherlands, and Germany, at which time customers in those nations will be notified.

Tandem Diabetes Care is a global insulin delivery and diabetes technology company headquartered in San Diego, California. Its pump portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump, both featuring the Control-IQ+ advanced hybrid closed-loop technology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment